
Bolt Biotherapeutics, Inc.
80
Recent developments highlight Bolt Biotherapeutics' narrowing operating losses, clinical pipeline progress, and strategic acquisition to bolster its oncology drug development.
- Bolt Biotherapeutics reported a narrowed operating loss of $4.7 million in Q3 2026, reflecting improved expense management [N1].
- The company anticipates Phase 2 clinical data for its PRA-216 candidate in Q2 2027 [N1].
- Bolt Biotherapeutics acquired Prana Therapies, Inc. and secured $120 million through a private placement to advance the PRA-216 pipeline in October 2026 [N5][N6].
- Data for the BDC-4182 candidate is expected in Q3 2026, indicating ongoing clinical progress [N7].
- The company reported a net loss of $4.422 million for the quarter ended September 30, 2026, with no revenue generated during the period [S2].
- Liquidity remains solid with $13.78 million in cash and equivalents and a current ratio of 2.05 as of September 30, 2026 [S2].
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company specializing in oncology therapeutics. Its business model centers on developing novel cancer treatments through clinical trials of its pipeline candidates, including PRA-216, BDC-4182, and BDC-3042. The company recently expanded its pipeline and financial resources by acquiring Prana Therapies, Inc. and securing $120 million in a private placement. Financially, Bolt Biotherapeutics reported no revenue for the quarter ended September 30, 2026, and a net loss of $4.422 million, reflecting ongoing investment in research and development. The company maintains liquidity with over $13 million in cash and equivalents and a current ratio above 2.0, indicating sufficient short-term financial resources to support operations. Clinical progress includes upcoming data readouts for key pipeline candidates, which are critical milestones in its development strategy.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Bolt Biotherapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company advancing multiple therapeutic candidates. The company reported a net loss of $4.422 million for Q3 2026 with no revenue, holding approximately $13.78 million in cash and $1.02 million in short-term investments as of September 30, 2026. Recent corporate developments include the acquisition of Prana Therapies and a $120 million private placement to support the PRA-216 pipeline. Clinical milestones include anticipated Phase 2 data for PRA-216 in Q2 2027 and data for BDC-4182 expected in Q3 2026. The company has been narrowing operating losses and managing expenses while progressing its oncology pipeline [S2][N1][N5][N7].
The company is advancing multiple oncology drug candidates through clinical trials, with key data readouts anticipated for PRA-216 and BDC-4182. The recent acquisition of Prana Therapies and a $120 million private placement provide additional financial resources to support pipeline development. Narrowing operating losses and expense management indicate improving operational efficiency. Successful clinical milestones could enhance the company's development prospects and pipeline value.
Bolt Biotherapeutics operates without current revenue and reports ongoing net losses, reflecting the high-risk nature of clinical-stage biopharmaceutical development. Clinical trial outcomes are uncertain and delays or negative results could impact pipeline viability. The company’s liquidity, while sufficient as of Q3 2026, may require further capital raises to sustain operations. Competition in oncology therapeutics is intense, and regulatory hurdles remain significant risks. The company’s dependence on successful clinical progress and financing exposes it to execution and market risks.
Bolt Biotherapeutics' moat is primarily based on its proprietary oncology drug candidates and clinical-stage pipeline, which represent potential novel therapies in cancer treatment. The company's acquisition of Prana Therapies and the associated capital raise enhance its development capabilities and pipeline breadth. However, as a clinical-stage biopharmaceutical company without commercial products or revenue, its competitive advantage depends heavily on successful clinical trial outcomes and regulatory approvals. Intellectual property rights, specialized scientific expertise, and strategic partnerships may contribute to its moat, but these factors are typical in the biotech sector and subject to high risk and competition.
• Clinical Development Risk: The success of Bolt Biotherapeutics depends on positive clinical trial outcomes for its drug candidates. Failure or delays in trials could adversely affect the company’s prospects.
• Financial Risk: The company currently operates at a net loss with no revenue, relying on capital raises and financing to fund operations. Insufficient liquidity or inability to raise capital could impact development activities.
• Regulatory Risk: Bolt Biotherapeutics must obtain regulatory approvals for its drug candidates, which involves complex and uncertain processes that could delay or prevent commercialization.
• Competitive Risk: The oncology therapeutics market is highly competitive with many companies developing similar or alternative treatments, which could limit market opportunities.
Business trends: Progress in oncology pipeline development with key clinical data milestones and narrowing operating losses alongside active expense management.
Execution milestones: Completion of Prana Therapies acquisition and $120 million financing to support PRA-216; clinical data readouts for PRA-216 Phase 2 and BDC-4182.
Key risks: Uncertainty in clinical trial outcomes, ongoing net losses requiring capital, regulatory approval challenges, and competitive pressures in oncology therapeutics.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology therapeutics.
- The company has a pipeline including candidates such as PRA-216, BDC-4182, and BDC-3042.
- Bolt Biotherapeutics acquired Prana Therapies, Inc. and secured $120 million through a private placement to advance the PRA-216 pipeline as of October 2026.
- The company reported a narrowing operating loss of $4.7 million in Q3 2026.
- PRA-216 Phase 2 clinical data is anticipated in Q2 2027.
- BDC-4182 clinical data is anticipated in Q3 2026.
- Bolt Biotherapeutics reported a net loss of $4.422 million for the quarter ended September 30, 2026, with basic and diluted EPS of -2.25 USD per share.
- The company had cash and cash equivalents of approximately $13.78 million and short-term investments of about $1.02 million as of September 30, 2026.
- Current assets totaled $17.08 million and current liabilities were $8.32 million at the end of Q3 2026, resulting in a current ratio of 2.05 and a cash ratio of 1.78.
- The company reported zero revenue for the quarter ended September 30, 2026.
- Bolt Biotherapeutics has been actively managing expenses, with losses narrowing in recent quarters.
- The company is progressing clinical trials and anticipates key data readouts for its oncology pipeline.
- Recent news coverage includes multiple quarterly financial results and clinical updates, reflecting ongoing development activities.
Generated 2026-11-14
- S1 | 2026-03-12 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Bolt Biotherapeutics Q3 Operating Loss Narrows To $4.7 Mln; PRA-216 Phase 2 Data Expected In Q2 2027 | https://www.nasdaq.com/articles/bolt-biotherapeutics-q3-operating-loss-narrows-47-mln-pra-216-phase-2-data-expected-q2
- N2 | 2026-11-09 | www.nasdaq.com | Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/coherus-oncology-chrs-reports-q3-loss-lags-revenue-estimates
- N3 | 2026-11-06 | www.nasdaq.com | Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/caribou-biosciences-inc-crbu-reports-q3-loss-beats-revenue-estimates
- N4 | 2026-11-04 | www.nasdaq.com | Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates | https://www.nasdaq.com/articles/adaptive-biotechnologies-adpt-q3-earnings-and-revenues-top-estimates
- N5 | 2026-10-23 | www.nasdaq.com | Bolt Biotherapeutics, Inc. Acquires Prana Therapies, Inc. and Secures $120 million Private Placement | https://www.nasdaq.com/articles/bolt-biotherapeutics-inc-acquires-prana-therapies-inc-and-secures-120-million-private
- N6 | 2026-10-23 | www.nasdaq.com | Bolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement | https://www.nasdaq.com/articles/bolt-biotherapeutics-announces-acquisition-prana-therapies-120-mln-concurrent-private
- N7 | 2026-08-24 | www.nasdaq.com | Bolt Biotherapeutics Q2 Loss Narrows As Expenses Decline; BDC-4182 Data Expected In Q3 | https://www.nasdaq.com/articles/bolt-biotherapeutics-q2-loss-narrows-expenses-decline-bdc-4182-data-expected-q3
- N8 | 2026-08-11 | www.nasdaq.com | Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/bolt-biotherapeutics-inc-bolt-reports-q2-loss-misses-revenue-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


